Fulcrum Therapeutics (FULC) Short Interest Ratio & Short Volume $2.99 -0.02 (-0.66%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Fulcrum Therapeutics Short Interest DataFulcrum Therapeutics (FULC) has a short interest of 4.97 million shares. This marks a -9.96% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.1, indicating that it would take 3.1 days of the average trading volume of 829,371 shares to cover all short positions.Current Short Interest4,970,000 sharesPrevious Short Interest5,520,000 sharesChange Vs. Previous Month-9.96%Dollar Volume Sold Short$15.71 millionShort Interest Ratio3.1 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares53,940,000 sharesPercentage of Shares Shorted9.21%Today's Trading Volume782,323 sharesAverage Trading Volume829,371 sharesToday's Volume Vs. Average94% Short Selling Fulcrum Therapeutics? Sign up to receive the latest short interest report for Fulcrum Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartFULC Short Interest Over TimeFULC Days to Cover Over TimeFULC Percentage of Float Shorted Over Time Ad Crypto 101 MediaBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…YES, I WANT THE #1 CRYPTO NOW Fulcrum Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/20244,970,000 shares $15.71 million -10.0%N/A3.1 $3.16 10/15/20245,520,000 shares $20.20 million -6.4%N/A3.3 $3.66 9/30/20245,900,000 shares $21.06 million -48.3%N/A3.5 $3.57 9/15/202411,400,000 shares $36.25 million +41.4%N/A6.8 $3.18 8/31/20248,060,000 shares $68.91 million -1.1%N/A8.7 $8.55 8/15/20248,150,000 shares $78.97 million +6.1%N/A9 $9.69 Get the Latest News and Ratings for FULC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/20247,680,000 shares $71.27 million +5.8%N/A8.8 $9.28 7/15/20247,260,000 shares $61.35 million +37.2%N/A9.3 $8.45 6/30/20245,290,000 shares $32.80 million +36.3%N/A7.2 $6.20 6/15/20243,880,000 shares $28.91 million +8.1%N/A6.8 $7.45 5/31/20243,590,000 shares $28.18 million +16.2%N/A6.7 $7.85 5/15/20243,090,000 shares $25.49 million +3.0%N/A5 $8.25 4/30/20243,000,000 shares $21.39 million +18.6%N/A5 $7.13 4/15/20242,530,000 shares $18.62 million +12.0%N/A4 $7.36 3/31/20242,260,000 shares $21.33 million -5.4%N/A3.4 $9.44 3/15/20242,390,000 shares $27.15 million -25.3%N/A3.4 $11.36 2/29/20243,200,000 shares $32.67 million -0.6%N/A4.5 $10.21 2/15/20243,220,000 shares $30.27 million -4.7%N/A5.1 $9.40 1/31/20243,380,000 shares $24.40 million -16.3%N/A5.5 $7.22 1/15/20244,040,000 shares $28.68 million +10.1%N/A6.7 $7.10 12/31/20233,670,000 shares $24.77 million +10.2%N/A6.5 $6.75 12/15/20233,330,000 shares $17.95 million -18.0%N/A6.2 $5.39 11/30/20234,060,000 shares $19.49 million +9.7%N/A7.8 $4.80 11/15/20233,700,000 shares $15.47 million -6.3%N/A6.1 $4.18 10/31/20233,950,000 shares $14.38 million +1.0%N/A2 $3.64 10/15/20233,910,000 shares $15.21 million -2.7%N/A1.9 $3.89 9/30/20234,020,000 shares $17.85 million +7.5%N/A2 $4.44 9/15/20233,740,000 shares $16.79 million +5.1%N/A1.8 $4.49 8/31/20233,560,000 shares $19.69 million +30.4%N/A1.7 $5.53 8/15/20232,730,000 shares $11.55 million -22.2%N/A1.3 $4.23 7/31/20233,510,000 shares $13.41 million +0.3%N/A5 $3.82 7/15/20233,500,000 shares $12.88 million -4.1%N/A4.6 $3.68 6/30/20233,650,000 shares $12.05 million -19.3%N/A4.6 $3.30 6/15/20234,520,000 shares $13.74 million +9.4%N/A5.3 $3.04 5/31/20234,130,000 shares $11.23 million +4.8%N/A4.1 $2.72 5/15/20233,940,000 shares $14.34 million -17.6%N/A3.2 $3.64 4/30/20234,780,000 shares $11.95 million -6.6%N/A3.9 $2.50 4/15/20235,120,000 shares $12.34 million +3.6%N/A4.2 $2.41 3/31/20234,940,000 shares $14.08 million +25.1%N/A3.8 $2.85 3/15/20233,950,000 shares $15.01 million -2.5%N/A3.1 $3.80When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! 2/28/20234,050,000 shares $24.46 million +7.7%N/A3.8 $6.04 2/15/20233,760,000 shares $48.69 million +6.2%N/A3.8 $12.95 1/31/20233,540,000 shares $44.64 million +6.6%N/A4.6 $12.61 1/15/20233,320,000 shares $45.48 million -7.3%N/A4.6 $13.70 12/30/20223,580,000 shares $26.06 million +21.0%N/A5.7 $7.28 12/15/20222,960,000 shares $16.22 million -9.2%N/A6.1 $5.48 11/30/20223,260,000 shares $22.33 million -4.4%N/A8.5 $6.85 11/15/20223,410,000 shares $24.48 million -2.0%N/A8.9 $7.18 10/31/20223,480,000 shares $19.35 million +0.6%N/A8 $5.56 10/15/20223,460,000 shares $25.95 million -3.9%N/A7.5 $7.50 9/30/20223,600,000 shares $29.12 million -7.2%N/A8.4 $8.09 9/15/20223,880,000 shares $35.31 million +13.8%N/A8.4 $9.10 8/31/20223,410,000 shares $25.23 million +5.3%N/A5.3 $7.40 8/15/20223,240,000 shares $25.34 million -8.2%N/A4.6 $7.82 7/31/20223,530,000 shares $20.76 million -6.1%12.0%4.8 $5.88 7/15/20223,760,000 shares $20.27 million +1.4%12.8%5.1 $5.39 6/30/20223,710,000 shares $18.18 million +6.6%12.6%4.3 $4.90 6/15/20223,480,000 shares $15.35 million -7.0%11.8%3.9 $4.41 5/31/20223,740,000 shares $26.63 million +9.4%12.7%5 $7.12 5/15/20223,420,000 shares $28.32 million -21.7%11.6%4.7 $8.28 4/30/20224,370,000 shares $42.04 million +63.1%15.1%6.4 $9.62 4/15/20222,680,000 shares $35.48 million -0.4%9.3%4.4 $13.24 3/31/20222,690,000 shares $63.62 million -5.0%9.3%5.4 $23.65 3/15/20222,830,000 shares $44.52 million +12.8%9.8%6.6 $15.73 2/28/20222,510,000 shares $27.61 million -4.9%8.4%6 $11.00 2/15/20222,640,000 shares $29.81 million +25.7%8.8%6.5 $11.29 1/31/20222,100,000 shares $25.54 million +17.3%7.2%4.7 $12.16 1/15/20221,790,000 shares $24.92 million -2.7%N/A0 $13.92 12/31/20211,840,000 shares $32.55 million +8.2%6.1%4.1 $17.69 12/15/20211,700,000 shares $28.56 million -18.7%5.6%3.4 $16.80 11/30/20212,090,000 shares $30.31 million -31.0%6.9%3.9 $14.50 11/15/20213,030,000 shares $54.12 million +47.1%10.0%5.5 $17.86 10/29/20212,060,000 shares $45.61 million -0.5%6.9%0.6 $22.14 10/15/20212,070,000 shares $53.82 million +0.5%6.8%0.6 $26.00 9/30/20212,060,000 shares $58.11 million +21.2%6.7%0.6 $28.21 9/15/20211,700,000 shares $45.85 million +4.9%5.9%0.5 $26.97 8/31/20211,620,000 shares $48.11 million -35.5%6.2%0.5 $29.70 8/13/20212,510,000 shares $57.55 million +261.2%13.1%0.8 $22.93 7/30/2021695,000 shares $5.08 million -7.4%4.4%0.4 $7.31 7/15/2021750,400 shares $7.02 million -12.2%4.7%4.9 $9.36 6/30/2021855,000 shares $8.96 million +29.1%5.4%6 $10.48 6/15/2021662,500 shares $5.59 million -2.4%4.2%5.9 $8.44 5/28/2021678,600 shares $6.06 million -5.4%4.3%7.7 $8.93 5/14/2021717,100 shares $7.09 million -3.6%4.5%8 $9.89 4/30/2021743,500 shares $8.35 million -3.6%4.8%7.4 $11.23 4/15/2021771,100 shares $9.23 million +0.5%3.6%6.4 $11.97 3/31/2021767,600 shares $8.77 million +8.9%3.6%5.4 $11.43 3/15/2021705,000 shares $8.62 million +2.0%3.3%4.6 $12.22 2/26/2021691,000 shares $8.82 million -4.6%3.2%4.6 $12.77 2/12/2021724,100 shares $9.70 million +2.4%3.5%4.5 $13.40When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! 1/29/2021707,500 shares $7.96 million -21.8%4.1%4.3 $11.25 1/15/2021904,800 shares $10.27 million -9.5%5.3%5.3 $11.35 12/31/20201,000,000 shares $12.69 million +13.2%6.8%6 $12.69 12/15/2020883,700 shares $11.80 million -5.1%6.0%4.7 $13.35 11/30/2020931,000 shares $10.74 million -9.6%6.3%4.6 $11.54 11/15/20201,030,000 shares $13.03 million -22.0%7.0%5.1 $12.65 10/30/20201,320,000 shares $13.11 million +9.1%9.7%5.5 $9.93 10/15/20201,210,000 shares $13.64 million +5.2%8.9%5 $11.27 9/30/20201,150,000 shares $9.12 million +34.6%8.5%5.4 $7.93 9/15/2020854,200 shares $6.65 million +14.7%6.3%4.3 $7.78 8/31/2020745,000 shares $5.42 million +91.8%5.5%4.2 $7.27 8/14/2020388,400 shares $2.96 million -22.2%2.9%2.5 $7.62 7/31/2020499,200 shares $7.92 million +6.1%3.6%4.4 $15.87 7/15/2020470,600 shares $8.31 million -37.3%3.4%5.5 $17.66 6/30/2020751,000 shares $13.74 million +35.6%6.5%9 $18.29 6/15/2020553,700 shares $9.62 million +2.1%5.6%6.6 $17.37 5/29/2020542,600 shares $10.80 million -0.9%5.5%6.2 $19.91 5/15/2020547,400 shares $9.14 million -6.8%5.6%6 $16.69 4/30/2020587,200 shares $7.41 million +2.3%6.3%6.9 $12.62 4/15/2020574,300 shares $6.23 million +23.4%6.2%6.5 $10.85 3/31/2020465,400 shares $5.25 million +74.3%5.0%4.8 $11.29 3/13/2020267,000 shares $2.83 million +17.4%N/A3.8 $10.60 2/28/2020227,400 shares $2.16 million +26.7%N/A3.3 $9.49 2/14/2020179,500 shares $2.33 million +29.9%1.9%2.6 $13.00 1/31/2020138,200 shares $2.53 million +16.1%1.5%2 $18.29 1/15/2020119,000 shares $1.93 million +19.6%1.3%1.8 $16.20 12/31/201999,500 shares $1.69 million -54.2%1.1%1.5 $17.00 FULC Short Interest - Frequently Asked Questions What is Fulcrum Therapeutics' current short interest? Short interest is the volume of Fulcrum Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, traders have sold 4,970,000 shares of FULC short. Learn More on Fulcrum Therapeutics' current short interest. What is a good short interest ratio for Fulcrum Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. FULC shares currently have a short interest ratio of 3.0. Learn More on Fulcrum Therapeutics's short interest ratio. Which institutional investors are shorting Fulcrum Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Fulcrum Therapeutics: Jane Street Group LLC, Wolverine Trading LLC, Sphera Funds Management LTD., Ikarian Capital LLC, LMR Partners LLP, and Belvedere Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Fulcrum Therapeutics' short interest increasing or decreasing? Fulcrum Therapeutics saw a drop in short interest in October. As of October 31st, there was short interest totaling 4,970,000 shares, a drop of 10.0% from the previous total of 5,520,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Fulcrum Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Fulcrum Therapeutics: bluebird bio, Inc. (24.54%), Kezar Life Sciences, Inc. (2.87%), Sangamo Therapeutics, Inc. (9.10%), Exscientia plc (2.55%), AnaptysBio, Inc. (23.75%), ORIC Pharmaceuticals, Inc. (16.51%), Dianthus Therapeutics, Inc. (25.20%), Oculis Holding AG (0.06%), Tourmaline Bio, Inc. (10.44%), Stoke Therapeutics, Inc. (12.65%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Fulcrum Therapeutics stock? Short selling FULC is an investing strategy that aims to generate trading profit from Fulcrum Therapeutics as its price is falling. FULC shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Fulcrum Therapeutics? A short squeeze for Fulcrum Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of FULC, which in turn drives the price of the stock up even further. How often is Fulcrum Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including FULC, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies bluebird bio Short Interest Data Kezar Life Sciences Short Interest Data Sangamo Therapeutics Short Interest Data Phathom Pharmaceuticals Short Interest Data Exscientia Short Interest Data ORIC Pharmaceuticals Short Interest Data AnaptysBio Short Interest Data Stoke Therapeutics Short Interest Data Oculis Short Interest Data Tourmaline Bio Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:FULC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
